Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1105-1108

  Wang, Shu ^a   An, Ruifang ^a   Han, Xiaobing ^a   Zhu, Kexiu ^a   Xue, Yan ^a  

^a First Affiliated Hospital   (China)

Author keywords

Chemotherapy; Gestational trophoblastic tumors; High risk; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LIVER ENZYME; METHOTREXATE; VINCRISTINE;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS;

EID: 33751409100     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.031     Document Type: Article

References (28)

1. McNeish I.A., Strickland S., Holden L., Rustin G.J., Foskett M., Seckl M.J., et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J. Clin. Oncol. 20 (2002) 1838-1844
2. Matsui H., Suzuka K., Yamazawa K., Tanaka N., Mitsuhashi A., Seki K., et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol. Oncol. 96 (2005) 616-620
3. Michael E.C. Treatment of low Risk gestational trophoblastic disease. Clin. Obstet. Gynecol. 46 (2003) 579-592
4. Curry S.L., Blessing J.A., DiSaia P.J., et al. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet. Gynecol. 73 (1989) 357-362
5. Newlands E.S., Bagshawe K.D., Begent R.H., et al. Developments in chemotherapy for medium-and high-risk patients with gestational trophoblastic tumours (1979-1984). Br. J. Obstet. Gynaecol. 93 (1986) 63-69
6. Newlands E.S., Bagshawe K.D., Begent R.H., et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to1989. Br. J. Obstet. Gynaecol. 98 (1991) 550-557
7. Bower M., Newlands E.S., Holden L., et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J. Clin. Oncol. 15 (1997) 2636-2643
8. Soper J.T., Evans A.C., Clarke-Pearson D.L., et al. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet. Gynecol. 83 (1994) 113-117
9. Kim S.J., Bae S.N., Kim J.H., et al. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol. Oncol. 71 (1998) 247-253
10. Soto-Wright V., Goldstein D.P., Bernstein M.R., et al. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol. Oncol. 64 (1997) 156-159
11. Matsui H., Suzuka K., Iitsuka Y., et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol. Oncol. 78 (2000) 28-31
12. Theodore C., Azab M., Droz J.P., et al. Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer 64 (1989) 1824-1828
13. Bakri Y.N., Subhi J., Amer M., et al. Liver metastases of gestational trophoblastic tumor. Gynecol. Oncol. 48 (1993) 110-113
14. Bakri Y., Berkowitz R.S., Goldstein D.P., et al. Brain metastases of gestational trophoblastic tumor. J. Reprod. Med. 39 (1994) 179-184
15. Surwit E.A., and Childers J.M. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen. J. Reprod. Med. 36 (1991) 45-48
16. Kohorn E.I., Goldstein D.P., Hancock B.W., Kim S.J., Lurain J.R., Newlands E., et al. Combining the staging system of the International Federation of gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of Working Committee of the International Society for the Study of Trophoblastic Disease and International Gynecological Cancer Society. Int. J. Cynecol. Cancer 10 (2000) 84-88
17. Garrett A.P., Garner E.O., Goldstein D.P., et al. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J. Report. Med. 47 (2002) 355-362
18. Kwon J.S., Elit L., Mazurka J., et al. Weekly intravenous methotrexate with folinic acid for nonmetastatic gestational trophoblastic neoplasia. Gynecol. Oncol. 82 (2001) 367-370
19. Berkowitz R.S., Goldstein D.P., and Bernstein M.R. Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecol. Oncol. 36 (1990) 56-59
20. Hoffman M.S., Fiorica J.V., Gleeson N.C., et al. A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Gynecol. Oncol. 60 (1996) 292-294
21. Wong L.C., Choo Y.C., and Ma H.K. Primary oral etoposide therapy in gestational trophoblastic disease: an update. Cancer 58 (1986) 14-17
22. Rustin G.J., Newlands E.S., Lutz J.M., et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J. Clin. Oncol. 14 (1996) 2769-2773
23. Schink J.C., Singh D.K., Rademaker A.W., Miller D.S., and Lurain J.R. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet. Gynecol. 80 (1992) 817-820
24. John R., Lurain T., and Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol. Oncol. 97 (2005) 618-623
25. Jason D.W., and David G.M. Treatment of high-risk gestational trophoblastic tumors. Clin. Obstet. Gynecol. 46 (2003) 593-606
26. Lurain J.R. Advances in management of high-risk gestational trophoblastic tumors. J. Reprod. Med. 47 (2002) 451-459
27. Escobar P.F., Lurain J.R., Singh D.K., Bozorgi K., and Fishman D.A. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine chemotherapy. Gynecol. Oncol. 91 (2003) 552-557
28. Bolis G., Bonazzi C., Landoni F., Mangili G., Vergadoro F., and Mangioni C. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol. Oncol. 31 (1988) 439-444